力尔凡联合α-干扰素和白细胞介素-2治疗肾癌的临床观察

Clinical Study on Combination of Lifein,α-Interferon and Interleukin-2in the Treatment of Renal Cell Carcinoma

目的:评价力尔凡联合α-干扰素(IFN-α)和白细胞介素-2(IL-2)治疗肾癌根治术后患者的疗效。方法:80例肾癌根治术后患者随机分为两组:治疗组40例采用力尔凡联合IFN-α和IL-2治疗;对照组40例不加力尔凡余同治疗组。结果:1)治疗组术后1年生存率(100%),3年生存率(90.0%)明显高于对照组。2)免疫功能:治疗组治疗后与治疗前相比CD3、CD4、CD4/CD8值及NK细胞数均明显升高而CD8值下降,均与对照组相比有显著性差异。3)治疗组白细胞下降幅度明显低于对照组,具有显著性差异。结论:肾癌根治术后应用力尔凡联合IFN-α和IL-2治疗,可以提高生存率,增强免疫功能,对抗IFN-α所致的白细胞下降。

Objective:To evaluate the effects of Lifein combined withα-interferon (IFN-α)and interleukin-2(IL-2)in the treatment of renal cell carcinoma after radical nephrectomy.Methods:80patients with renal cell carcinoma after radical nephrectomy were divided randomly into two groups:Treatment group including40cases treated with Lifein,IFN-αand IL-2;Another40cases as the control group were treated with IFN-αand IL-2of the same injection method and the same dose.Results:1)The3years(90%)survival rate was significantly higher than that of the control group.2)Immune functions:after being treated,the values of CD3、CD4、CD4/CD8and the counts of NK cell were increased significantly.While the values of CD8were decreased in the Lifein group as compared with control group.3)The decrease of leucocyte count was sig-nifi cantly less serious in the Lifein group than that of control group.Conclusion:Lifein has some functions of enhancing the treatment efficacy and the immunofunctions treated with IFN-αand IL-2,revers ing the decrease of leucocyte counts induced by IFN-αin the treatment of renal cell car-cinoma after radical nephrectomy.